Dr. Martens (LON:DOCS) Stock Price Down 11% – Here’s Why

Dr. Martens plc (LON:DOCS)’s stock price dropped 11% during trading on Tuesday . The company traded as low as GBX 66.51 and last traded at GBX 67.34. Approximately 1,309,415 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 1,614,594 shares. The stock had previously closed at GBX 75.65.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Up 4.0%

The business has a fifty day moving average of GBX 75.88 and a 200-day moving average of GBX 83.26. The stock has a market cap of £660.64 million, a PE ratio of 40.21, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities research analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Robert Hanson acquired 96,000 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were bought at an average cost of GBX 79 per share, with a total value of £75,840. Insiders have purchased 97,130 shares of company stock worth $7,673,816 over the last 90 days. Company insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.